回盛生物(300871) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥274,460,009.01, representing a 30.59% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥19,893,333.71, an increase of 8.11% year-on-year, but a significant decrease of 77.95% year-to-date[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,978,010.55, up 3.43% for the quarter, but down 83.51% year-to-date[5]. - The company's basic earnings per share for Q3 2022 was ¥0.12, a 9.09% increase from the previous quarter, but a decrease of 77.78% year-to-date[5]. - The net profit for Q3 2022 was CNY 26,405,977.46, a decrease from CNY 119,728,893.47 in the same period last year, representing a decline of approximately 78%[20]. - Operating profit for Q3 2022 was CNY 30,433,524.16, down from CNY 138,122,968.60 year-over-year, indicating a decrease of about 78%[20]. - The company reported a decrease in sales revenue from CNY 771,279,447.62 in the previous year to CNY 666,798,759.38 in Q3 2022, a decline of approximately 13.5%[22]. - The basic and diluted earnings per share for Q3 2022 were both CNY 0.16, down from CNY 0.72 in the same period last year, a decrease of about 77.8%[20]. - The company reported a net profit margin decline due to increased operating costs, impacting overall profitability[19]. - The company's total profit for Q3 2022 was CNY 28,460,408.21, significantly lower than CNY 137,767,113.63 in the same quarter of the previous year, indicating a decline of about 79%[20]. Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was ¥73,333,293.95, down 38.68% compared to the previous year[5]. - The net cash flow from operating activities for the first nine months of 2022 was ¥73,333,293.95, a decrease of 38.68% compared to ¥119,590,909.85 in the same period of 2021, primarily due to an increase in accounts receivable[9]. - The net cash flow from investing activities was -¥800,628,862.76, a significant decline of 1,488.89% from -¥50,389,141.10 in the previous year, mainly due to increased purchases of financial products[9]. - The net cash flow from financing activities decreased to -¥55,047,377.41, down 1,089.15% from ¥5,565,130.91, primarily due to increased cash repayments of loans[9]. - The net increase in cash and cash equivalents was -¥782,282,322.99, a decrease of 1,146.48% compared to an increase of ¥74,753,982.87 in the previous year, mainly due to net outflows from investing activities[9]. - Cash flow from operating activities for Q3 2022 was CNY 73,333,293.95, compared to CNY 119,590,909.85 in the previous year, reflecting a decline of approximately 39%[22]. - Total cash flow from investing activities was negative CNY 800,628,862.76 in Q3 2022, worsening from negative CNY 50,389,141.10 in the same period last year[22]. - Cash flow from financing activities resulted in a net outflow of CNY 55,047,377.41 in Q3 2022, compared to a net inflow of CNY 5,565,130.91 in the previous year[23]. - The total cash and cash equivalents at the end of Q3 2022 stood at CNY 183,858,359.05, down from CNY 360,261,233.85 at the end of Q3 2021[23]. - The company's total assets at the end of Q3 2022 were ¥2,770,809,269.95, a 1.06% increase from the end of the previous year[5]. - The company's total assets as of September 30, 2022, amounted to CNY 2,770,809,269.95, slightly up from CNY 2,741,662,030.01 at the beginning of the year[18]. - Cash and cash equivalents were CNY 323,047,579.17, down from CNY 1,068,233,710.99 at the beginning of the year, indicating a significant liquidity reduction[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,259, with no preferred shareholders having restored voting rights[11]. - Wuhan Tongsheng Investment Co., Ltd. held 49.86% of the shares, amounting to 82,800,000 shares, with 7,500,000 shares pledged[11]. - The company repurchased a total of 1,522,850 shares, representing 0.92% of the total share capital, with a total transaction amount of ¥30,947,790.28[13]. Expenses and Liabilities - Management expenses increased by 34.81% year-to-date, primarily due to higher salaries and depreciation[8]. - The company experienced a 306.86% increase in financial expenses year-to-date, attributed to the capitalization of convertible bond interest[8]. - Current liabilities totaled CNY 593,053,059.52, an increase of 17.83% from CNY 503,268,977.63 in the previous period[17]. - The total non-current liabilities were CNY 618,392,189.95, showing a slight decrease from CNY 619,539,266.83 in the previous period[17]. - The total equity attributable to shareholders decreased to CNY 1,559,364,020.48 from CNY 1,618,853,785.55, reflecting a decline of 3.6%[18]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[19]. - The company has not disclosed any new product or technology developments, market expansions, or mergers and acquisitions in the current report[12].